Drug Profile
Adipose derived autologous mesenchymal stem cell therapy - Celltex Therapeutics
Alternative Names: AdMSCsLatest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Celltex Therapeutics
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Alzheimer's disease
- No development reported Macular degeneration; Multiple sclerosis; Osteoarthritis
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Osteoarthritis in USA (IV, Infusion)
- 23 Aug 2021 Celltex Therapeutics plans a phase II trial in COVID-2019 infections (IV) (NCT05017298)
- 22 Apr 2021 Clinical trials in Alzheimer's disease (Parenteral) (NCT04855955)